Although there is little evidence to link histone modification and LOXL2 expression, evaluations in breast cancer cell lines reveal that treatment with a general DNA methylation inhibitor, 5-azacytidine, resulted in a 40-fold upregulation of LOXL2 mRNA expression, and further co-treatment with a histone deacetylase inhibitor, trichostatin A, resulted in a further 5-fold expression increase [28,97]. Here, LOXL2 is linked to breast carcinoma.